Prevention of venous thromboembolism in cancer using low-molecular-weight heparins

Pathophysiology of Haemostasis and Thrombosis

Volumn 27, Issue 1, 1997, Pages 32-37

  Kakkar, A K ^a   Williamson, R C N ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Cancer; Low molecular weight heparins; Venous thromboembolism

Indexed keywords

ANTINEOPLASTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; TAMOXIFEN;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURGERY; CONFERENCE PAPER; DISEASE ASSOCIATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; OVARY CARCINOMA; PANCREAS CARCINOMA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; THROMBOEMBOLISM; THROMBOSIS PREVENTION; VEIN THROMBOSIS;

HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASMS; THROMBOPHLEBITIS;

EID: 0030664735     PISSN: 14248832     EISSN: 14248840     Source Type: Journal    
DOI: 10.1159/000217480     Document Type: Article

References (24)

1. Trousseau A: Phlagmasia alba do-lens; in Clinique Medicalc dc I’Ho-tcl-Dicu dc Paris, Paris, JB Balliere et Fils, 1865, vol 3, p 94.
2. Rickies FR, Edwards RL: Activation of blood coagulation in cancer: T rousseau’s syndrome revisited., Blood 1983;62:14-31.
3. Kakkar AK, DeRuvo N, Chin-swangwatanakul V, Tebbutt S, Williamson RCN: Extrinsic-pathway activation in cancer with high factor Vila and tissue factor., Lancet 1995: 346:1004-1005.
4. Shen VS., Pollack EW: Fatal pulmonary embolism in cancer patients: Is heparin prophylaxis justified? South Med J 1980;73:841-843.
5. Kakkar VV, Howe CT, Nicolaides AN, Renny JT, Clarke MB: Deep vein thrombosis of the leg., Is there a ‘high risk’ group? Am J Surg 1970; 120:527-530.
6. Claggett GP, Anderson FA., Heit J, Levine MN: Prevention of venous thromboembolism., Chest 1995:108 (supp 1):3128-3133.
7. Saphner T, Tormey DC, Gray R: Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer., J Clin Oncol 1991;9:286-294.
8. Pritchard KI, Paterson AH, Paul NA, Zee B, Fine S, Pater J: Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer., National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group., J Clin Oncol 1996;14:2731-2737.
9. Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Hryniuk W, De Pauw S: The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer., N Engl J Med 1988,318:404-407.
10. Goodnough LT, Saito H, Manni A, Jones PK, Pearson OH: Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen., A study of 159 patients., Cancer 1984;54:1264-1268.
11. Bern MM, Lokich JJ, Wallach SR, Bothc A Jr, Benotti PN, Arkin CF, Greco FA, Huberman M, Moore C: Very low doses of warfarin can prevent thrombosis in central venous catheters: A randomized prospective trial., Ann Intern Med 1990; 112: 423-428.
12. Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R, Abad A: Upper extremity deep vein thrombosis in cancer patients with venous access devices-prophylaxis with a low molecular weight heparin (Fragmin)., Thromb Haemost 1996; 75:251-253.
13. Clagett PG, Reisch JS: Prevention of venous thromboembolism in general surgical patients., Results of a meta-analysis., Ann Surg 1988:208: 227-240
14. Enoxaparin Study Group: Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with ve-nographic assessment., Br J Surg 1997;84:1099-1103.
15. Prevention of fatal postoperative pulmonary embolism by low doses of heparin., An international multicentre trial., Lancet 1975;2:45-51.
16. Gallus AS, Hirsh J, O’Brien SE, McBride JA, Tuttle RJ, Gent M: Prevention of venous thrombosis with small subcutaneous doses of heparin., JAMA 1976;235:1980-1982.
17. Kakkar VV, Cohen AT, Edmondson RA, Phillips MJ, Cooper DJ, Das SK, Maher KT, Sanderson RM, Ward VP, Kakkar S: Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery., Lancet 1993;341:259-265.
18. Bergqvist D, Burmark US, Flordal PA, Frisell J et al: Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 Xal units in 2070 patients., Br J Surg 1995;82:496-501.
19. Levine M, Hirsh J, Gent M, et al: Double-blind randomised trial of very low dose warfarin for the prevention of thromboembolism in Stage IV breast cancer., Lancet 1994; 343:886-889.
20. Rajan R, Gafni A, Levine M., Hirsh J, Gent M: Very low-dose warfarin prophylaxis to prevent thromboembolism in women with metastatic breast cancer receiving chemotherapy: An economic evaluation., J Clin Oncol 1995;13:42-46.
21. Lcbeau B, Chastang C, Brechot JM, Capron F, Dautzenberg B, Delaise-ments C, Mornet M., Brun J, Hurdc-bourcq JP, Lemarie E: Subcutaneous heparin treatment increases survival in small cell lung cancer., ‘Pctites Cellules’ Group., Cancer 1994;74:38-45.
22. Hull RD, Raskob GE, Pineo GF: Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis., N Engl J Med 1992;326:975-982 (abstract).
23. Prandoni P, Lensing AWA., Buller HRE: Comparison of subcutaneous low molecular weight heparin with intravenous standard heparin in proximal deep vein thrombosis., Lancet 1992;339:441-445 (abstract).
24. Green D., Hull RD, Brant R, Pineo GF: Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin (letter)., Lancet 1992;339:1476